ReviewNature reviews. Disease primers2020
Ebola virus disease.
Review in Nature reviews. Disease primers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 380 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
380 citing papers in PubMed, 6 syntheses or guidelines pooled it, 614 citations in OpenAlex.
- Clinical factors associated with mortality in ebola virus disease: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Acceptability of the Ebola vaccine in the sub-Saharan African population: A systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Systematic Review and Meta-Analysis of Emerging Viral Zoonotic Diseases, 2016-2026.Transboundary and emerging diseases · 2026Pooled it
- Mapping the research landscape of antibody therapy for Ebola virus disease: a bibliometric analysis.Frontiers in immunology · 2026Pooled it
- Investigation of the Status of Epidemiology, Pathophysiology, Virology, Clinical Symptoms, Diagnosis, Prevention, Treatment and Classification of Ebola Virus Disease (EVD): A Systematic Review.Infectious disorders drug targets · 2025Pooled it
- Asymptomatic viruses detectable in saliva in the first year of life: a narrative review.Pediatric research · 2024Pooled it
- Multiplexed detection of febrile infections using CARMEN.Nature communications · 2025Trial
- Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.Emerging microbes & infections · 2025Trial
- Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.Human vaccines & immunotherapeutics · 2024Trial
- Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib.Pharmaceutical science advances · 2026Review
- Ebola virus and Sudan virus infection in humans: a comparison to inform vaccine research and development.Emerging microbes & infections · 2026Review
- Rapid inactivation kinetics of a broad range of viruses on a continuously self-cleaning polymer surface.Bioactive materials · 2026Article
- Infection-associated acute kidney injury in resource-limited settings.Nature reviews. Nephrology · 2026Review
- Towards broader-spectrum direct-acting antivirals against RNA viruses.Nature reviews. Microbiology · 2026Review
- Emergence of a Bundibugyo virus variant in the 2026 outbreak in the Democratic Republic of the Congo and Uganda.Nature medicine · 2026Article
- Overcrowded Ebola treatment centers are fueling transmission in the Democratic Republic of the Congo.Nature medicine · 2026Article
- [Ebola virus disease-clinical relevance in intensive care and emergency medicine].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026Article
- Early Action Review of Detection, Notification, and Response Timeliness during Cross-Border Bundibugyo Virus Disease Outbreak, Uganda, 2026.Emerging infectious diseases · 2026Review
- Discovery of a 4'-Azido Fleximer Nucleoside Analog With Broad-Spectrum Antiviral Activity Against DENV, EBOV, and Other RNA Viruses.ChemMedChem · 2026Article
- Field Investigation of the Bundibugyo Ebola Virus Disease (BDBV) Outbreak in Ituri Province, Democratic Republic of the Congo: Challenges, Strategies, and Priority Actions for Outbreak Control-An Outbreak Investigation Review.Infectious disease reports · 2026Article
320 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 5 countries.
Funding
Abstract
Ebola virus disease (EVD) is a severe and frequently lethal disease caused by Ebola virus (EBOV). EVD outbreaks typically start from a single case of probable zoonotic transmission, followed by human-to-human transmission via direct contact or contact with infected bodily fluids or contaminated fomites. EVD has a high case-fatality rate; it is characterized by fever, gastrointestinal signs and multiple organ dysfunction syndrome. Diagnosis requires a combination of case definition and laboratory tests, typically real-time reverse transcription PCR to detect viral RNA or rapid diagnostic tests based on immunoassays to detect EBOV antigens. Recent advances in medical countermeasure research resulted in the recent approval of an EBOV-targeted vaccine by European and US regulatory agencies. The results of a randomized clinical trial of investigational therapeutics for EVD demonstrated survival benefits from two monoclonal antibody products targeting the EBOV membrane glycoprotein. New observations emerging from the unprecedented 2013-2016 Western African EVD outbreak (the largest in history) and the ongoing EVD outbreak in the Democratic Republic of the Congo have substantially improved the understanding of EVD and viral persistence in survivors of EVD, resulting in new strategies toward prevention of infection and optimization of clinical management, acute illness outcomes and attendance to the clinical care needs of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.